Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 20/20 | 1.00 |
| ▸ | FNTB | P49356 | 20/20 | 1.00 |
| ▸ | PGGT1B | P53609 | 18/20 | 1.00 |
| ▸ | DNAJA1 | P31689 | 2/20 | 0.69 |
| ▸ | KRAS | P01116 | 1/20 | 0.65 |
| ▸ | RAP1A | P62834 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6433388 | 0.90 | FNTA (0.82) | FNTAFNTBPGGT1BDNAJA1KCNH2 | |
| SCHEMBL7163748 | 0.86 | FNTA (1.00) | FNTAFNTBPGGT1BDNAJA1KRAS | |
| SCHEMBL7160573 | 0.86 | FNTA (1.00) | FNTAFNTBPGGT1BDNAJA1KRAS | |
| SCHEMBL7163961 | 0.86 | FNTA (1.00) | FNTAFNTBPGGT1BDNAJA1KRAS | |
| SCHEMBL7160377 | 0.86 | FNTA (0.82) | FNTAFNTBPGGT1BDNAJA1KRAS | |
| SCHEMBL7160351 | 0.85 | FNTA (1.00) | FNTAFNTBPGGT1BDNAJA1KRAS | |
| SCHEMBL7177668 | 0.84 | FNTA (1.00) | FNTAFNTBPGGT1BDNAJA1KRAS | |
| SCHEMBL7167481 | 0.84 | FNTA (0.84) | FNTAFNTBPGGT1BDNAJA1KRAS | |
| SCHEMBL7167930 | 0.84 | FNTA (0.83) | FNTAFNTBPGGT1BDNAJA1KRAS | |
| SCHEMBL7163181 | 0.84 | FNTA (0.72) | FNTAFNTBPGGT1BDNAJA1KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-15 | — | — | US | claimed |
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | claimed |
| US-6562823-B1 | Inhibition of farnesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar | MERCK & CO., INC. | 2003-05-13 | — | — | US | claimed |
| US-20240308979-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2022-11-22 | — | — | US | disclosed |
| US-20210387962-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2021-12-16 | — | — | US | disclosed |
| EP-3177608-B1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2019-09-18 | — | — | EP | disclosed |
| EP-2010528-B1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| US-9452998-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20160046605-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-02-18 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-6479512-B1 | TO TREAT TYROSINE KINASE-DEPENDENT DISEASES AND CONDITIONS, SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, ETC. | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020147203-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2002-10-10 | — | — | US | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
| US-6420382-B2 | QUINOLIN-2-ONE DERIVATIVES TO TREAT ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY AND INFLAMMATORY DISEASES | MERCK & CO., INC. | 2002-07-16 | — | — | US | disclosed |
| US-20020072526-A1 | Orally active salts with tyrosine kinase activity | MERCK & CO., INC. | 2002-06-13 | — | — | US | disclosed |
| US-20010047007-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2001-11-29 | — | — | US | disclosed |
| US-20010044451-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2001-11-22 | — | — | US | disclosed |
| US-6313138-B1 | FOR THERAPY OF ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES IN MAMMALS | MERCK & CO., INC. | 2001-11-06 | — | — | US | disclosed |
| US-6245759-B1 | PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES; ANTICARCINOGENIC AND ANTITUMOR AGENTS; ATHEROSCLEROSIS, ANGIOGENESIS INHIBITORS | MERCK & CO., INC. | 2001-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | FNTA 4/4885FNTB 19/4885PGGT1B 274/4885 |
| US-20020147203-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | FNTA 2966/4885FNTB 3554/4885PGGT1B 4287/4885 |
| US-20240308979-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | FNTA 1583/4885FNTB 1494/4885PGGT1B 2063/4885 |
| US-20210387962-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | FNTA 1583/4885FNTB 1494/4885PGGT1B 2063/4885 |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | PRKCA, PRKCB, PRKCH | FNTA 1583/4885FNTB 1494/4885PGGT1B 2063/4885 |
| US-20160046605-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | FNTA 1583/4885FNTB 1494/4885PGGT1B 2063/4885 |
| US-20020072526-A1 | Orally active salts with tyrosine kinase activity | TEK, FLT1, TIE1 | FNTA 3580/4885FNTB 4277/4885PGGT1B 3570/4885 |
| US-20010044451-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | FNTA 2966/4885FNTB 3554/4885PGGT1B 4287/4885 |
| US-20010047007-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | FNTA 2966/4885FNTB 3554/4885PGGT1B 4287/4885 |
| US-20050277629-A1 | Methods for the treatment of synucleinopathies (Lansbury) | SNCA, PARK7, NLN | FNTA 12/4885FNTB 44/4885PGGT1B 1996/4885 |
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | FNTA 2966/4885FNTB 3554/4885PGGT1B 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.